No specific pharmacological therapy (such as sulfonylureas used for KCNJ11 mutations [16]) is available for the initial phase of 6q24-TNDM-associated diabetes, but recognition of the etiology confirms that standard diabetes management is appropriate and that insulin can often be discontinued once remission is achieved. This evidence concerns the gene INS and diabetes mellitus.